UCB's Rystiggo can be used by the NHS as a backup treatment for people with the rare autoimmune and neuromuscular disease gMG, says NICE.

Official answer: Rystiggo (rozanolixizumab) may start working within one week of the first dose. In a clinical trial, patients saw...

Infusion day is usually one of my favorite days of the week. It’s the day hope arrives on a schedule. But this time, hope was overshadowed by exhaustion. Just days after an emergency room visit and my power port removal, what should have been a routine Rystiggo infusion became a reminder that chronic illness isn’t always about dramatic emergencies. Sometimes it’s the quiet accumulation of stress, uncertainty, and physical fatigue that brings you to your knees. In this deeply personal entry, I share the reality of balancing Myasthenia Gravis, Crohn’s Disease, work, family responsibilities, and the invisible weight of simply trying to keep going when your body is begging you to stop. It’s a story about tears, faith, perseverance, a failed attempt at self-medicating with a honey bun and a Starbucks Doubleshot, and ultimately, the simplest prayer I could pray: “Lord… I just need some peace.” Read the full diary entry and join me as I continue sharing the realities of living with invisible illness—one honest story at a time. 💜

UCB's Rystiggo can be used by the NHS as a backup treatment for people with the rare autoimmune and neuromuscular disease gMG, says NICE.

KORU Medical Systems has received the US FDA 510(k) clearance to use its FreedomEDGE infusion system for administering Rystiggo.

What is the current size and annual growth rate of the rystiggo market? The rystiggo market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compo...

Reported Thursday, Jan 29 - 4:13pm EST (TheFly subscription required to read more.)

/PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration...

UCB will showcase new data on its treatments RYSTIGGO® and ZILBRYSQ® for generalized myasthenia gravis at the 2025 AANEM Annual Meeting in San Francisco.

2026 outlook sees $47.5–$50M revenue and positive EBITDA and cash flow, as KORU gains RYSTIGGO clearance and EU MDR-ready Freedom60 pump.

.

.

Drug Trials Snapshots: RYSTIGGO

UCB will showcase 18 abstracts, including an oral presentation, demonstrating continued commitment to advancing targeted treatments for generalized myasthenia gravis (gMG). Presentations include new post hoc analyses considering corticosteroid dose tapering during treatment with RYSTIGGO®...